Nonmyeloablative HLA-Haploidentical (NMA Haplo) BMT with High-Dose Posttransplantation Cyclophosphamide (PTCy) Is Associated with Similar Outcomes to Matched BMT When Stratified By Disease Risk Index (DRI)

被引：0
|
作者：
McCurdy, Shannon R. [1 ]
Kanakry, Jennifer A. [1 ]
Showel, Margaret M. [1 ]
Tsai, Hua-Ling [1 ]
Bolanos-Meade, Javier [1 ]
Kanakry, Christopher G. [1 ]
Gladstone, Douglas E. [1 ]
Luznik, Leo [1 ]
Huff, Carol Ann [1 ]
Swinnen, Lode J. [1 ]
Ambinder, Richard F. [1 ]
Jones, Richard J. [1 ]
Fuchs, Ephraim J. [1 ]
Kasamon, Yvette L. [1 ]
机构：
[1] Johns Hopkins Univ, Baltimore, MD USA
来源：
BLOOD | 2014年 / 124卷 / 21期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 22 条
  • [1] Risk-stratified outcomes of nonmyeloablative HLA-haploidentical BMT with high-dose posttransplantation cyclophosphamide
    McCurdy, Shannon R.
    Kanakry, Jennifer A.
    Showel, Margaret M.
    Tsai, Hua-Ling
    Bolanos-Meade, Javier
    Rosner, Gary L.
    Kanakry, Christopher G.
    Perica, Karlo
    Symons, Heather J.
    Brodsky, Robert A.
    Gladstone, Douglas E.
    Huff, Carol Ann
    Pratz, Keith W.
    Prince, Gabrielle T.
    Dezern, Amy E.
    Gojo, Ivana
    Matsui, William H.
    Borrello, Ivan
    McDevitt, Michael A.
    Swinnen, Lode J.
    Smith, B. Douglas
    Levis, Mark J.
    Ambinder, Richard F.
    Luznik, Leo
    Jones, Richard J.
    Fuchs, Ephraim J.
    Kasamon, Yvette L.
    [J]. BLOOD, 2015, 125 (19) : 3024 - 3031
  • [2] Nonmyeloablative (NMA), HLA-Mismatched Unrelated Donor (mMUD) BMT with High-Dose Posttransplantation Cyclophosphamide (PTCy) Has Outcomes Similar to Matched BMT
    Kasamon, Yvette L.
    Fuchs, Ephraim J.
    Bolanos-Meade, Javier
    Leffell, Mary S.
    Zahurak, Marianna
    Rosner, Gary L.
    Powell, Jonathan D.
    Ambinder, Richard F.
    Jones, Richard J.
    Luznik, Leo
    [J]. BLOOD, 2015, 126 (23)
  • [3] Shortened-Duration Tacrolimus after Nonmyeloablative HLA-Haploidentical (NMA haplo) BMT with High-Dose Posttransplantation Cyclophosphamide (PTCy) Facilitates Strategies for Relapse Reduction
    Kasamon, Yvette L.
    Fuchs, Ephraim J.
    Zahurak, Marianna
    Rosner, Gary L.
    Symons, Heather J.
    Bolanos-Meade, Javier
    Jones, Richard J.
    [J]. BLOOD, 2016, 128 (22)
  • [4] Significance of Missing Inhibitory KIR Ligands in Nonmyeloablative, HLA-Haploidentical (Haplo) BMT with Posttransplantation High-Dose Cyclophosphamide (PT/Cy)
    Kasamon, Yvette L.
    Luznik, Leo
    Leffell, M. Sue
    Tsai, Hua-ling
    Symons, Heather J.
    Bolanos-Meade, Javier
    Rosner, Gary
    Morris, Lawrence E.
    Crilley, Pamela A.
    Jones, Richard J.
    Fuchs, Ephraim J.
    [J]. BLOOD, 2011, 118 (21) : 383 - 384
  • [5] SIGNIFICANCE OF HAPLOTYPE B DONORS AND GENE CONTENT MOTIFS IN NONMYELOABLATIVE, HLA-HAPLOIDENTICAL (Haplo) BMT WITH POSTTRANSPLANTATION HIGH-DOSE CYCLOPHOSPHAMIDE (PT/Cy)
    Symons, H. J.
    Munchel, A. T.
    Rossiter, N. L.
    Kasamon, Y. L.
    Jones, R. J.
    Fuchs, E. J.
    Leffell, M. S.
    [J]. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2012, 18 (02) : S218 - S218
  • [6] Graft-Versus-Host Disease (GVHD) and Survival Outcomes after HLA-Haploidentical (Haplo) Bone Marrow Transplant (BMT) Compare Favorably with Matched Related Donor (MRD), and Matched Unrelated Donor (MUD) BMT Utilizing High-Dose Posttransplantation Cyclophosphamide (PTCy)
    McCurdy, Shannon R.
    Kanakry, Christopher G.
    Kasamon, Yvette L.
    Meade, Javier Bolanos
    Tsai, Hua-Ling
    Showel, Margaret M.
    Kanakry, Jennifer A.
    Symons, Heather J.
    Rosner, Gary L.
    Fuchs, Ephraim J.
    Jones, Richard J.
    Luznik, Leo
    [J]. BLOOD, 2014, 124 (21)
  • [7] The Fountain of Youth: Outcomes of Nonmyeloablative (NMA), HLA-Haploidentical Related (Haplo) Bone Marrow Transplantation (BMT) with Post-Transplantation Cyclophosphamide (PTCy) Best with Younger Donors Regardless of Relationship to Patient
    Franklin, Clio E.
    Showel, Margaret M.
    Tsai, Hua-Ling
    Varadhan, Ravi
    McCurdy, Shannon R.
    Gladstone, Douglas E.
    Jones, Richard J.
    DeZern, Amy E.
    [J]. BLOOD, 2017, 130
  • [8] NONMYELOABLATIVE HLA-HAPLOIDENTICAL BONE MARROW TRANSPLANTATION (HAPLO-BMT) WITH POST-TRANSPLANT HIGH-DOSE CYCLOPHOSPHAMIDE (CY) IN PATIENTS WITH SEVERE HEMOGLOBINOPATHIES
    Bolanos-Meade, J.
    Lanzkron, S.
    Kemberling, H.
    Gamper, C.
    Ambinder, R. F.
    Luznik, L.
    Luznik, E. J.
    Jones, R. J.
    Brodsky, R. A.
    [J]. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2011, 17 (02) : S285 - S285
  • [9] Prospective study of nonmyeloablative, HLA-mismatched unrelated BMT with high-dose posttransplantation cyclophosphamide
    Kasamon, Yvette L.
    Ambinder, Richard F.
    Fuchs, Ephraim J.
    Zahurak, Marianna
    Rosner, Gary L.
    Bolanos-Meade, Javier
    Levis, Mark J.
    Gladstone, Douglas E.
    Huff, Carol Ann
    Swinnen, Lode J.
    Matsui, William H.
    Borrello, Ivan
    Brodsky, Robert A.
    Jones, Richard J.
    Luznik, Leo
    [J]. BLOOD ADVANCES, 2017, 1 (04) : 288 - 292
  • [10] Nonmyeloablative (NMA), HLA-Haploidentical (Haplo) Blood or Marrow Transplantation (BMT) from Non-First-Degree Related Donors Has Similar Outcomes to First-Degree Related BMT
    Elmariah, Hany
    Kasamon, Yvette L.
    Zahurak, Marianna
    Tucker, Noah
    Rosner, Gary
    Bolanos-Meade, F. Javier
    Varadhan, Ravi
    Fuchs, Ephraim J.
    DeZern, Amy E.
    Luznik, Leo
    Jones, Richard J.
    Ambinder, Richard F.
    [J]. BLOOD, 2017, 130
123